Last updated on June 2019

A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD


Brief description of study

This study will assess the efficacy and safety of 3 doses of PXL770 versus placebo after 12 weeks of treatment.

Detailed Study Description

The study will be performed in patients with Nonalcoholic Fatty Liver Disease. The primary endpoint will be the assessment of the change in the percentage of liver fat mass (assessed by MRI-PDFF).

Clinical Study Identifier: NCT03763877

Find a site near you

Start Over

Study Site 02

Los Angeles, CA United States
  Connect »

Study Site 01

Gainesville, FL United States
  Connect »

Study Site 11

Ocoee, FL United States
  Connect »

Study Site 10

Athens, GA United States
  Connect »

Study Site 03

Indianapolis, IN United States
  Connect »

Study Site 07

Marrero, LA United States
  Connect »

Study Site 05

West Monroe, LA United States
  Connect »

Study Site 08

Berlin, NJ United States
  Connect »

Study Site 09

Durham, NC United States
  Connect »

Study Site 13

Rapid City, SD United States
  Connect »

Study Site 14

Chattanooga, TN United States
  Connect »

Study Site 06

Arlington, TX United States
  Connect »

Study Site 04

San Antonio, TX United States
  Connect »

Study Site 12

San Antonio, TX United States
  Connect »